There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adaptimmune Therapeutics (ADAP – Research Report), Crinetics Pharmaceuticals (CRNX – Research Report) and PolyPid (PYPD – Research Report) with bullish sentiments.
Adaptimmune Therapeutics (ADAP)
In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Adaptimmune Therapeutics. The company’s shares closed last Wednesday at $0.56, close to its 52-week low of $0.52.
According to TipRanks.com, Frahm is a 4-star analyst with an average return of
Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.80, implying a 566.4% upside from current levels. In a report issued on October 31, Mizuho Securities also maintained a Buy rating on the stock with a $9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Crinetics Pharmaceuticals (CRNX)
In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Crinetics Pharmaceuticals, with a price target of $57.00. The company’s shares closed last Wednesday at $28.28.
PhD has an average return of
According to TipRanks.com, PhD is ranked #2161 out of 8601 analysts.
Crinetics Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $48.00, representing a 65.0% upside. In a report issued on October 26, Oppenheimer also maintained a Buy rating on the stock with a $46.00 price target.
PolyPid (PYPD)
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on PolyPid, with a price target of $13.00. The company’s shares closed last Tuesday at $4.24, close to its 52-week low of $3.57.
According to TipRanks.com, Buchanan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
PolyPid has an analyst consensus of Moderate Buy, with a price target consensus of $13.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADAP:
